Explore

Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Innate Pharma Announces Annual General Meeting for Shareholders

Innate Pharma Announces Annual General Meeting for Shareholders

Innate Pharma Announces Annual General Meeting for Shareholders
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment
Trendline Trendline
IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy
Trendline Trendline
San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development
Trendline Trendline
Frontier Medicines Appoints David R. Epstein to Board Amid Precision Medicine Expansion

Frontier Medicines Appoints David R. Epstein to Board Amid Precision Medicine Expansion

Frontier Medicines Appoints David R. Epstein to Board Amid Precision Medicine Expansion
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal
Trendline Trendline
Prothena Announces Leadership Changes to Drive Strategic Growth

Prothena Announces Leadership Changes to Drive Strategic Growth

Prothena Announces Leadership Changes to Drive Strategic Growth
Trendline Trendline
Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments

Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments

Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments
Trendline Trendline
Frontier Medicines Appoints David R. Epstein to Board, Enhancing Precision Medicine Development

Frontier Medicines Appoints David R. Epstein to Board, Enhancing Precision Medicine Development

Frontier Medicines Appoints David R. Epstein to Board, Enhancing Precision Medicine Development
Trendline Trendline
IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial